

## PRESS RELEASE

## **Kurma Partners invests in Feetme**

Kurma Partners led a €1.95 million Seed financing of FeetMe with Idinvest Partners, Paris Saclay Seed Fund and Seventure. Existing investor SOS Ventures also participated in the round. Alain Horvais, Partner at Kurma will join the board of directors of the company.

**FeetMe,** a certified medical company is developing movement analysis solutions based on connected insoles. The innovative technology of FeetMe allows real-time and real-life conditions gait analysis. The proprietary technology combines pressure sensors, motion sensors and learning algorithms to analyse patients and athletes functional capacity as well as empower rehabilitation among patients suffering from gait disorders. « Our investment in FeetMe confirms our positionning into Digital Health space » says Alain Horvais.

100 million people worldwide suffer from gait disorders. Gait disorders are often a forerunner and indicator among evolutive diseases such as multiple sclerosis, Parkinson disease, fragility among elderly, peripheral neuropathies and diabetic foot problems. Quantifying disease status and progression can be a real challenge for both physicians and patients without real life data. Today only subjective tools such as clinical scales exist to quantify and qualify mobility. They lack of sensitivity to help adapting therapeutic treatments.

"This seed round will help us pursue the development of our product to target therapeutics areas in collaboration with market players" announces Alexis Mathieu, founding CEO at FeetMe. "The connected insole allows patient and physician to manage and evaluate in real time and remotely treatments efficacy to adapt them more precisely and without constraints for the patient. Creating new digital biomarkers will reinforce existing therapeutics with companion diagnostic and monitoring solution".

Please contact Philippe (pp@kurmapartners.com) for further information.

Kurma team